GLPwatch
Trulicity for Bipolar disorder
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for bipolar disorder, and any use for this condition is off-label or investigational. Research includes studies on immune modulation in the central nervous system and reports of psychiatric adverse effects linked to dulaglutide, but these do not establish efficacy for bipolar disorder.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | Bipolar disorder |
| Approval status | Investigational / off-label |
| Research papers | 2 |
Trulicity is not FDA-approved for bipolar disorder; the research below reflects investigational or off-label study only.